The effect of Adalimumab in the treatment of patients with chronic schizophrenia
Phase 2
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20090117001556N126
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Diagnosis of positive and negative symptoms based on DSM-5
Attending hospital with a psychosis attack
Age between 18 to 60 years old
Exclusion Criteria
Head trauma
History of shock therapy during past three months prior to the trial
Undergoing neurosurgery
Presence of acute or chronic systemic diseases
History of allergy to the medication used in this research
Receiving any anti-psychotic medications during past eight weeks prior to the trial
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of schizophrenia. Timepoint: Baseline and weeks 4 and 8. Method of measurement: By Positive and Negative Syndrome Scale (PANSS).
- Secondary Outcome Measures
Name Time Method